Results 1 to 10 of about 13,477 (288)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study [PDF]

Clinical Ophthalmology, 2018
Mario A Economou,1 Helene Kolstad Laukeland,2,3 Iwona Grabska-Liberek,4 Jean-François Rouland5 1Anterior Segment Department, St Erik’s Eye Hospital, Karolinska Institute, Stockholm, Sweden; 2Department of Ophthalmology, University Hospital,
Economou MA, Laukeland HK, Grabska-Liberek I, Rouland JF   +3 more
doaj   +4 more sources

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease

Pharmaceuticals, 2022
To compare the efficacy, patient-reported satisfaction, and safety of preservative-free (PF)-tafluprost, PF-dorzolamide/timolol and preservative-containing (P)-latanoprost in Korean glaucoma patients with ocular surface disease (OSD).
Sang-Woo Park, Jiwoong Lee, Michael S. Kook   +2 more
doaj   +2 more sources

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients

Journal of Ophthalmology, 2021
Aim. Within the clinical setting, some patients have been identified as lacking in response to PGAs. This meta-analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG/OHT patients, latanoprost ...
Ziyan Cai, Mengdan Cao, Ke Liu, Xuanchu Duan   +3 more
doaj   +2 more sources

Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study. [PDF]

Clin Ophthalmol
Jason Bacharach,1 Ehsan Sadri,2 Gagan Sawhney,3 Casey Kopczynski,4 Mohinder M Merchea4 1North Bay Eye Associates, Inc, Petaluma, CA, USA; 2Visionary Eye Institute, Newport Beach, CA, USA; 3Georgia Eye Partners, Atlanta, GA, USA; 4Alcon, Inc, Fort Worth ...
Bacharach J, Sadri E, Sawhney G, Kopczynski C, Merchea MM.   +4 more
europepmc   +2 more sources

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study [PDF]

BMC Ophthalmology, 2008
Background The stability of ophthalmic preparations in multidose containers is influenced by the preservative as well as the stability of the active ingredient.
Umbelino Cristiano C, Kasahara Niro, Paolera Mauricio D, Walt John G   +3 more
doaj   +5 more sources

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma [PDF]

Clinics, 2020
OBJECTIVES: Timolol maleate has been reported to be a safer intraocular pressure (IOP) lowering treatment than latanoprost. The United States Food and Drug Administration approved latanoprostene bunod, a nitric oxide-donating prodrug of latanoprost, for ...
Yulong Wang, Yue Liao, Xin Nie
doaj   +2 more sources

Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye [PDF]

International Journal of Nanomedicine, 2012
Jayaganesh V Natarajan1*, Marcus Ang2*, Anastasia Darwitan1, Sujay Chattopadhyay3, Tina T Wong2, Subbu S Venkatraman1 1Materials Science and Engineering, Nanyang Technological University, Singapore; 2Singapore Eye Research Institute, Singapore; 3Polymer ...
Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS   +5 more
doaj   +4 more sources

Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension [PDF]

BMC Ophthalmology, 2007
Background To determine monthly cost and cost effectiveness of bilateral prostaglandin/prostamide therapy for lowering intraocular pressure (IOP) in patients taking bimatoprost 0.03% (Lumigan®, Allergan, Inc.), latanoprost 0.005% (Xalatan®, Pfizer, Inc.),
Frenkel Ronald EP, Frenkel Max, Toler Allison   +2 more
doaj   +3 more sources

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients [PDF]

Clinical Ophthalmology, 2009
Makoto Ishikawa1,2, Takeshi Yoshitomi11Department of Ophthalmology, Akita University Faculty of Medicine, Akita, Japan; 2Department of Ophthalmology, Ogachi Central Hospital, Akita, JapanPurpose: To study the effect of the concomitant use of brinzolamide
Makoto Ishikawa, Takeshi Yoshitomi
doaj   +3 more sources

Latanoprost in the treatment of glaucoma

Clinical Ophthalmology, 2014
Albert AlmDepartment of Neuroscience, Ophthalmology, University Hospital, Uppsala, SwedenAbstract: Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma.
Alm A
doaj   +5 more sources